CARM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, CARISMA Therapeutics's Shareholder Yield % was 39.85%.
The historical data trend for CARISMA Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Shareholder Yield % | - | - | - | 30.09 |
CARISMA Therapeutics Quarterly Data | ||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shareholder Yield % | Get a 7-Day Free Trial | -118.90 | 1.20 | 4.56 | 30.09 | 15.54 |
For the Biotechnology subindustry, CARISMA Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's Shareholder Yield % falls into.
CARISMA Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2024 is calculated as:
Shareholder Yield % | = | Dividend Yield % | + | Buyback Yield % | + | Net Debt Paydown Yield % |
= | 0 % | + | -9.7 % | + | 25.24 % | |
= | 15.54 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
CARISMA Therapeutics (NAS:CARM) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Thank you for viewing the detailed overview of CARISMA Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Modernatx, Inc. | 10 percent owner | 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Steven Kelly | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Chidozie Ugwumba | director | 158 FILMORE STREET, DENVER CO 80206 |
Michael Klichinsky | officer: Chief Scientific Officer | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Michael Torok | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Regina Hodits | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bjorn Odlander | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
Minori Rosales | officer: Chief Development Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Jewett Michael A. S. | director | C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Patricia M. Drake | officer: Chief Commercial Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Elly Ryu | officer: Principal Accounting Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire • 09-05-2023
By PRNewswire • 06-28-2023
By PRNewswire • 11-28-2023
By PRNewswire • 11-22-2023
By PRNewswire • 08-10-2023
By PRNewswire • 06-26-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire PRNewswire • 05-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.